261 related articles for article (PubMed ID: 36238302)
1. Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma.
Gu X; Wei S; Li Z; Xu H
Front Immunol; 2022; 13():1022149. PubMed ID: 36238302
[TBL] [Abstract][Full Text] [Related]
2. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
3. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-SaccĂ M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma.
Ling B; Huang Z; Huang S; Qian L; Li G; Tang Q
Oncol Res; 2021 Mar; 28(6):561-578. PubMed ID: 32471520
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
[TBL] [Abstract][Full Text] [Related]
7. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
9. Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and treatment patterns for patients with early-stage pulmonary adenocarcinoma.
Jiang A; Chen X; Zheng H; Liu N; Ding Q; Li Y; Fan C; Fu X; Liang X; Tian T; Ruan Z; Yao Y
Int J Med Sci; 2022; 19(4):711-728. PubMed ID: 35582412
[No Abstract] [Full Text] [Related]
10. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-SaccĂ M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
12. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
13. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
14. Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.
Wu XN; Su D; Mei YD; Xu MQ; Zhang H; Wang ZY; Li LL; Peng L; Jiang JY; Yang JY; Li DJ; Cao H; Xia ZW; Zeng WJ; Cheng Q; Zhang N
Cancer Immunol Immunother; 2021 Oct; 70(10):2835-2850. PubMed ID: 33659999
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
17. Development of an invasion score based on metastasis-related pathway activity profiles for identifying invasive molecular subtypes of lung adenocarcinoma.
Han T; Liu Y; Zhou J; Guo J; Xing Y; Xie J; Bai Y; Wu J; Hu D
Sci Rep; 2024 Jan; 14(1):1692. PubMed ID: 38243040
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment.
Huang D; Tang E; Zhang T; Xu G
Front Immunol; 2022; 13():916284. PubMed ID: 35860256
[TBL] [Abstract][Full Text] [Related]
19. Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment.
Cheng W; Xu B; Zhang H; Fang S
Thorac Cancer; 2021 Sep; 12(18):2458-2467. PubMed ID: 34328274
[TBL] [Abstract][Full Text] [Related]
20. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]